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Abstract
Background: The role of vitamins in the combat of disease is usually conceptualized as acting by modulating the immune
response of an infected, eukaryotic host. We hypothesized that some vitamins may directly influence the growth of
prokaryotes, particularly mycobacteria.
Methods: The effect of four fat-soluble vitamins was studied in radiometric BactecH culture. The vitamins were A (including
a precursor and three metabolites,) D, E and K. We evaluated eight strains of three mycobacterial species (four of M. avium
subspecies paratuberculosis (MAP), two of M. avium and two of M. tb. complex).
Principal Findings: Vitamins A and D cause dose-dependent inhibition of all three mycobacterial species studied. Vitamin A
is consistently more inhibitory than vitamin D. The vitamin A precursor, b-carotene, is not inhibitory, whereas three vitamin
A metabolites cause inhibition. Vitamin K has no effect. Vitamin E causes negligible inhibition in a single strain.
Significance: We show that vitamin A, its metabolites Retinyl acetate, Retinoic acid and 13-cis Retinoic acid and vitamin D
directly inhibit mycobacterial growth in culture. These data are compatible with the hypothesis that complementing the
immune response of multicellular organisms, vitamins A and D may have heretofore unproven, unrecognized, independent
and probable synergistic, direct antimycobacterial inhibitory activity.
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Introduction
Since early in the last century [1] the role of both vitamin A (see
[2] for review) and vitamin D (see [3,4] for review) in combating
infectious diseases has been investigated. It is noteworthy that in
the vast majority of studies, the underlying assumption has been
that any efficacy of these vitamins in combating disease is
consequent to enhancement of the immune response of the
infected host [5–8]. There is no direct inhibition of bacterial
growth by synthetic retinoids [9]. In contrast retinaldehyde (but
not Retinoic Acid itself) inhibit Gram positive (but not Gram
negative) bacteria in culture [10].
The activities of vitamins A & D have been extensively reported
in relation to the host immune response in mycobacterial diseases
[4,8,11–15]. We posit that vitamins will have fundamental and
necessary activity in both prokaryotes as well as eukaryotes. We
hypothesized that vitamins A and D might directly inhibit
prokaryotic growth in general and mycobacterial growth in
particular. Any direct inhibitory action of vitamins would be in
addition to (and possibly synergistic with) their effect on the
immune response of a mycobacterial-infected host [5–8].
We herein report on radiometric culture studies of the four fat-
soluble vitamins (A, D, E & K) as well at the vitamin A precursor
b–carotene and three vitamin A metabolites (retinyl acetate,
retinoic acid and 13-cis retinoic acid) on three mycobacterial
species. They are the acknowledged human pathogen M.
Tuberculosis (M. tb.) complex, M. avium subspecies avium (M. avium)
pathogenic in immuno-compromised humans and the possibly
zoonotic M. avium subspecies paratuberculosis (MAP) [16].
Methods
This study was approved by the Research & Development
Committee at the VAMC Bronx NY (0720-06-038) and was
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e29631conducted under the Institutional Radioactive Materials Permit
(#31-00636-07).
Bacterial Culture
Our BactecH 460 (Becton-Dickinson Franklin Lakes NJ)
14C
radiometric culture inhibition methods have previously been
published in detail [17–22]. This system quantifies bacterial
growth, or lack thereof, by providing
14C in palmitate, an energy
source for mycobacterial growth [23]. Vials are assayed on a daily
basis, quantifying the amount of
14C released as
14CO2, by the
integral detector in the Bactec 460. The data are obtained as a
manufacturer determined, arbitrary Growth Units (GU) of 0-999.
Because the Bactec 460 is only semi-automatic, and the onerous
regulatory requirements of using radionucleotides, this exquisitely
sensitive [18] system is being phased out. It is being replaced by
the fully automatic, oxygen consumption detecting fluorescent
probe MIGT system (Becton-Dickerson NJ.) [24,25]
The detergent Tween 80 (recommended to minimize mycobac-
terial clumping [23]) is not used in culture, because of interference
with the assay [21,26]. Strains with the least spontaneous clumping
are studied instead. Except for the amount of test agent, every vial
has the identical concentration of all constituents (including
identical 3.2% concentration of the dissolving agent, DMSO.) In
this study, performed in singlicate, eight strains of mycobacteria,
four of which are MAP, are evaluated. Two MAP strains had been
isolated from humans with Crohn disease ‘‘Dominic’’ (ATCC
43545; Originally isolated by R. Chiodini [27]) and UCF 4 (gift of
Saleh Naser, Burnett College of Biomedical Sciences, University of
Central Florida, Orlando FL.) [28]. The other two MAP strains
were from ruminants with Johne disease, ATCC 19698 and 303
(gift of Michael Collins Madison WI.) The M. avium subspecies avium
strains (hereinafter called M. avium) were ATCC 25291 (veterinary
source) and M. avium 101 (Human isolate from a patient with AIDS;
Gift of Clark Inderlied PhD. UC Los Angles CA.) [29]. To study the
M. tuberculosis complex, we used two BioSafety level 2 strains;
Bacillus Calmette Guerin (BCG) M. bovis Karlson & Lessel (ATCC
19015) and an avirulent M. tb strain; ATCC 25177 (all ATCC from
ATCC Rockville MD).
The fat soluble vitamins studied were: vitamin A (Retinol;
Axerophthol, -3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-
2,4,6,8-nonatetraen-1-ol: Sigma Cat # R7632.) The vitamin A
precursor studied was b–Carotene (b,b-Carotene, Provitamin A:
Sigma Cat # 22040.) We studied three vitamin A metabolites;
Retinyl acetate (Retinol acetate, vitamin A acetate: Sigma Cat #
R3250) and Retinoic acid (ATRA, Tretinoin, vitamin A acid, all-
trans-Retinoic acid: SigmaCat# R2625).Additionally weevaluated
13 cis-Retinoic acid (Isotretinoin, AcutaneH Sigma Cat # R3255), a
medication used to treat intractable acne and occasionally
associated with the manifestation of both Crohn’s disease and
ulcerative colitis. A commercial source of another structural analog
of retinoic acid; 9-cis-Retinoic acid could not be identified.
The other three fat-soluble vitamins studied are: vitamin D
(Cholecalciferol; (+)-Vitamin D3, 7-Dehydrocholesterol activated,
Activated 7-dehydrocholesterol: Sigma Cat # C9576). Vitamin E
((6)-a-Tocopherol DL-all-rac-a-Tocopherol: Sigma Cat # T3251).
Vitamin K1 (2-Methyl-3-phytyl-1,4-naphthoquinone, 3-Phytylme-
nadione, Phylloquinone: Sigma Cat # 95271). Our inhibitory
antibiotic control is monensin [20] and the non-inhibitory control is
the gluterimide antibiotic, phthalimide [21]. (All Sigma, St Louis.
MO.) Chemicals are dissolved in DMSO, aliquoted, stored at
280uC, thawed, used once and discarded. Agents are studied at
concentrations ranging from 0.1 to 64 mg/ml.
For clarity and ease of understanding the same data are
presented in two ways. For individual mycobacteria we present
data from a single experiment graphically (Figures 1–9). These
data are presented as the cumulative Growth Index (cGI.) In
contrast, for each individual chemical agent studied, data are
presented in Tables as the ‘‘percent change from control cGI’’
(Inhibition as ‘‘%–DcGI’’; See [18] for calculation: Tables 1–10).
For simplicity and comprehensibility the data in each of
Figues 1–6 are for only two of the four agents tested. For ease of
comparison the inhibitory (Monensin) and non-inhibitory control
(Phthalimide) are repetitively presented. Data for vitamins A & D
are presented in Figure 1 (MAP), Figure 2 (M. avium) & Figure 3
(M. tb. complex) and vitamins E & K are presented in Figure 4
(MAP), Figure 5 (M. avium) & Figure 6 (M. tb. complex.) The
vitamin A precursor and structural analogs are presented in
tabular form. (b-Carotene; Table 7: Retinol acetate; Table 8:
Retinoic acid; Table 9: and 13-cis Retinoic acid; Table 10.) Data
for vitamin A precursors and analogs on mycobacterial species and
subspecies are presented as Figures (MAP=Figure 7: M.
avium=Figure 8 & M. tb. complex=Figure 9.).
Results
In this study we show that all MAP and both M. tb complex
strains are inhibited by Monensin (Table 1 and Figures 1 & 4 &
Table 1 & Figures 3 & 6.) This corroborates our previous findings
with Monensin [20,21,30]. As previously [20,21,30], Monensin
does not inhibit one of our two M. avium control strains (M. avium
101: Table 1 and Figures 2 & 5), attesting to the reliability and
reproducibility of our assay.
The non-inhibitory control that we use is Phthalimide, a
gluterimide antibiotic that has no mycobacterial inhibition [21]. In
this study, as previously [21,30,31], Phthalimide has no dose-
dependent inhibition against any of the mycobacterial strains
tested (Table 2 and Figures 1–6.)
Vitamin A causes dose dependent inhibition of all MAP, M.
avium and M. tb complex strains studied (Table 3 & Figures 1, 2 &
3) with 98%-DcGI at 16 mg/ml for MAP ATCC 19698. The
precursor to vitamin A, b-Carotene has no dose dependent
inhibition on six of eight mycobacterial strains and negligible
inhibition on two MAP strains (Table 7 & Figures 7, 8 & 9.) In
contrast, the three vitamin A metabolites (Figures 7, 8 & 9); retinyl
acetate (Table 8), retinoic acid (Table 9), and 13-cis retinoic acid
(Table 10) result in dose dependent inhibition of all three species
studied, but with intriguing interspecies variations. Retinyl Acetate
is most active against MAP (Figure 7 & Table 8; Dominic 96%-
DcGI at 64 mg/ml.) Retinoic acid and 13-cis retinoic acid are most
active against M. tb (98%-DcGI at 16 mg/ml), but have no
inhibition against BCG (Figure 9 & Tables 9 & 10.) M. avium is the
least susceptible to these vitamin A metabolites (Figure 8 &
Tables 8–10).
Vitamin D causes dose dependent inhibition of all MAP strains
studied (Table 3 & Figure 1). However, vitamin D is not as potent
an inhibitor against the two MAP human isolates (UCF-4; 56%-
DcGI at 64 mg/ml and Dominic) as it is on the two MAP bovine
isolates (Table 4 and Figure 1.) Likewise, vitamin D inhibits all M.
avium (Table 4 & Figure 2) and M. tb. complex (Table 4 & Figure 3)
strains studied. Finally, vitamin D is less effective than vitamin A
against all four M. avium and M. tb complex strains studied
(Tables 3 & 4 and Figures 1–3.).
In contrast, vitamin E (Table 5; Figures 4, 5, & 6) results in
inhibition of only one of the eight mycobacterial strains studied,
MAP Dominic (Table 5 & Figure 4.) Even then, the maximal
inhibition of vitamin E on Dominic (44%-DcGI at 64 mg/ml;
(Table 5 & Figure 4) is far less than is observed with either vitamin
Ao rD .
Vitamins A & D Inhibit Mycobacteria
PLoS ONE | www.plosone.org 2 January 2012 | Volume 7 | Issue 1 | e29631Figure 2. Both vitamins A & D inhibit M. avium. The inhibitory
control is Monensin, and the non-inhibitory control is Phthalimide. Note
that as previously [20,21,30], Monensin does not inhibit M avium 101.
cGI=cumulative Growth Index.
doi:10.1371/journal.pone.0029631.g002
Figure 3. Both vitamins A & D inhibit the M. tb complex. Vitamin
D is less effective against M. tb ATCC 25177. The inhibitory control is
Monensin, and the non-inhibitory control is Phthalimide. cGI=cumu-
lative Growth Index.
doi:10.1371/journal.pone.0029631.g003
Figure 1. Both vitamins A & D inhibit all four MAP strains studied. Strains from the two upper panels (UCF-4 & Dominic) were isolated from
humans with Crohn disease. Strains in the two lower panels were isolated from ruminants with Johne disease. The inhibitory control is Monensin, and
the non-inhibitory control is Phthalimide. cGI=cumulative Growth Index.
doi:10.1371/journal.pone.0029631.g001
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PLoS ONE | www.plosone.org 3 January 2012 | Volume 7 | Issue 1 | e29631Figure 4. Neither vitamins E nor K inhibit MAP (other than limited inhibition by vitamin E on Dominic.) The inhibitory control is
Monensin, and the non-inhibitory control is Phthalimide. cGI=cumulative Growth Index.
doi:10.1371/journal.pone.0029631.g004
Figure 5. Neither vitamins E nor K inhibit M. avium. The inhibitory
control is Monensin, and the non-inhibitory control is Phthalimide. Note
that as previously [20,21,30], Monensin does not inhibit M avium 101.
cGI=cumulative Growth Index.
doi:10.1371/journal.pone.0029631.g005
Figure 6. Neither vitamins E nor K inhibit the M. tb. complex.
The inhibitory control is Monensin, and the non-inhibitory control is
Phthalimide. cGI=cumulative Growth Index.
doi:10.1371/journal.pone.0029631.g006
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PLoS ONE | www.plosone.org 4 January 2012 | Volume 7 | Issue 1 | e29631Figure 7. The effects of vitamin A precursors and metabolites on MAP. ß-carotene, the precursor to vitamin A, exhibits no inhibition at the
doses studied. Maximal inhibitory activity against all MAP strains is observed with Retinyl acetate (solid black triangles.) Both Retinoic acid and 13-cis
Retinoic acid exhibit intermediate inhibition.
doi:10.1371/journal.pone.0029631.g007
Figure 8. The effects of vitamin A precursors and metabolites
on M. avium. ß-carotene, the precursor to vitamin A, exhibits no
inhibition at the doses studied. Retinyl acetate and 13-cis Retinoic acid
have some inhibition.
doi:10.1371/journal.pone.0029631.g008
Figure 9. The effects of vitamin A precursors and metabolites
on M. tb. complex. ß-carotene, the precursor to vitamin A, exhibits no
inhibition at the doses studied. Both Retinoic acid and 13-cis Retinoic
acid result in dose dependent inhibition on our avirulent strain of M. tb.
There is no comparable inhibition against Bacillus Calmette-Guerin
(BCG).
doi:10.1371/journal.pone.0029631.g009
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mg/ml MAP M. Avium M. tb. Complex
Human Isolate
Bovine
Isolate M. tb. BCG
UCF-4 Dominic 19698 303 25291 101 25177 19015
1 256% 221% 255% 227% 236% 26% 274% 228%
4 287% 244% 287% 266% 247% 22% 298% 254%
16 294% 278% 294% 291% 280% 21% 299% 273%
64 297% 288% 297% 296% 294% 0% 299% 291%
doi:10.1371/journal.pone.0029631.t001
Table 2. Phthalimide Non-Inhibitory Control.
mg/ml MAP M. Avium M. tb. Complex
Human Isolate
Bovine
Isolate M. tb. BCG
UCF-4 Dominic 19698 303 25291 101 25177 19015
1 11% 29% 22% 7% 239% 28% 215% 21%
4 11% 211% 27% 5% 240% 23% 25% 7%
16 7% 217% 25% 4% 239% 0% 27% 10%
64 21% 228% 222% 8% 232% 249% 215% 2%
doi:10.1371/journal.pone.0029631.t002
Table 3. Vitamin A: retinol.
mg/ml MAP M. Avium M. tb. Complex
Human Isolate
Bovine
Isolate M. tb. BCG
UCF-4 Dominic 19698 303 25291 101 25177 19015
1 217% 25% 220% 21% 20% 227% 224% 22%
4 261% 267% 268% 277% 28% 234% 248% 225%
16 295% 296% 298% 297% 278% 280% 291% 295%
64 299% 299% 299% 299% 299% 299% 299% 299%
doi:10.1371/journal.pone.0029631.t003
Table 4. Vitamin D Cholecalciferol.
mg/ml MAP M. Avium M. tb. Complex
Human Isolate
Bovine
Isolate M. tb. BCG
UCF-4 Dominic 19698 303 25291 101 25177 19015
1 222% 237% 26% 22% 15% 229% 225% 23%
4 232% 263% 224% 271% 241% 257% 226% 264%
16 248% 291% 293% 294% 275% 288% 238% 291%
64 256% 290% 296% 296% 268% 287% 260% 291%
doi:10.1371/journal.pone.0029631.t004
Table 5. Vitamin E DL-a-Tocopherol Acetate.
mg/ml MAP M. Avium M. tb. Complex
Human Isolate
Bovine
Isolate M. tb. BCG
UCF-4 Dominic 19698 303 25291 101 25177 19015
1 225% 212% 4% 25% 14% 227% 218% 19%
4 213% 222% 6% 1% 212% 213% 210% 23%
16 27% 233% 212% 2% 21% 211% 217% 1%
64 238% 244% 231% 1% 229% 233% 221% 16%
doi:10.1371/journal.pone.0029631.t005
Table 6. Vitamin K1.
mg/ml MAP M. Avium M. tb. Complex
Human Isolate
Bovine
Isolate M. tb. BCG
UCF-4 Dominic 19698 303 25291 101 25177 19015
1 219% 29% 3% 23% 212% 216% 3% 8%
41 1 % 215% 210% 12% 210% 17% 210% 1%
16 29% 226% 228% 5% 241% 232% 211% 230%
64 26% 264% 214% 221% 264% 229% 229% 239%
doi:10.1371/journal.pone.0029631.t006
Table 7. b-Carotene.
mg/ml MAP M. Avium M. tb. Complex
Human Isolate
Bovine
Isolate M. tb. BCG
UCF-4 Dominic 19698 303 25291 101 25177 19015
1 28% 2% 24% 2% 11% 226% 222% 11%
4 29% 24% 230% 2% 20% 214% 225% 13%
16 13% 28% 231% 25% 8% 210% 221% 13%
64 214% 225% 236% 23% 29% 232% 232% 21%
doi:10.1371/journal.pone.0029631.t007
Table 8. Retinyl Acetate.
mg/ml MAP M. Avium M. tb. Complex
Human Isolate
Bovine
Isolate M. tb. BCG
UCF-4 Dominic 19698 303 25291 101 25177 19015
1 21% 2% 214% 5% 36% 28% 22% 3%
4 274% 264% 232% 216% 18% 1% 3% 22%
16 282% 286% 268% 265% 213% 289% 27% 214%
64 295% 296% 292% 296% 284% 266% 278% 296%
doi:10.1371/journal.pone.0029631.t008
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PLoS ONE | www.plosone.org 6 January 2012 | Volume 7 | Issue 1 | e29631Vitamin K has no effect on the growth on any of the three
mycobacterial species studied (Table 6; Figures 4, 5, & 6.).
Discussion
To our knowledge this is the first study showing dose-dependent
inhibition, in radiometric culture, of three mycobacterial species
(the M. tb. complex, M. avium and MAP) by two of four fat-soluble
vitamins; vitamins A & D. In contrast, vitamin K has no, and
vitamin E negligible effect. These therefore provide appropriate
non-inhibitory experimental controls. Our observations cannot be
ascribed to the acidic nature of vitamin A or its analogs as the pH
remains within the manufacturer’s recommended range of
pH 6.662 in the final 5 ml incubation volume (data not presented.)
The mechanism(s) by which vitamins A & D inhibit mycobacterial
growth,andwhethertheyhavesimilarinhibitiononvirulentand/or
multi-drug resistant M. tb., remains to be determined.
Our finding are directly contradictory to those of Flemetakis
et. al. who concluded that there was no direct retinoid effect on
bacteria in vivo [9]. Others find that vitamin A and retinoic acid
have no antibacterial activity, whereas retinaldehyde does [10].
Neither study evaluated mycobacteria in radiometric culture. We,
and others [32], conclude that when evaluating mycobacterial
growth kinetics, liquid radiometric [23] data provide exquisitely
sensitive data of bacteriostatic in addition to bactericidal effects.
Inhibition of mycobacterial growth by vitamins A & D has been
ascribed to down regulation of the tryptophan-aspartate-containing
coat protein (TACO) gene in the human macrophage [8,33]. Our
dataarecompatible withan additionalhypothesis.Itisthat vitamins
D, A and vitamin A metabolites have a heretofore unproven,
independent and probable synergistic antimycobacterial inhibitory
action that complements the immune response of multicellular
organisms.
The vitamin A precursor, b-Carotene, does not inhibit mycobac-
terial growth. This indicates that mycobacterial mechanisms to
convert b-Carotene to vitamin A are inadequate to produce sufficient
vitamin A levels to inhibit mycobacterial growth. We conclude that
the subspecies specific, idiosyncratic, inhibition of the three vitamin A
metabolites merit further study, as do structural analogs of vitamin D.
We posit that multiple agents have underappreciated activity
against prokaryotes in addition to well-documented eukaryotic
activity. For example, we [17,18,20–22,30,31], and others [34,35],
have shown inhibition of MAP growth with medications used to
treat ‘‘autoimmune’’ and ‘‘inflammatory’’ diseases. In the present
study we show direct inhibition of mycobacterial growth by
vitamins A and D in culture. We conclude that the scientific
community has neglected the potential direct prokaryotic effects of
vitamins, emphasizing instead the indirect role that vitamins have
in enhancing the immune response of an infected host.
Our radiometric assay [23] is sufficiently sensitive to identify
mycobacterial growth enhancement in culture [31]. Using it, we
have corroborated the classic study of Bernheim in 1940 [36]
showing that salicylic acid increased oxygen consumption by the
tuberculosis bacillus. Additionally, we showed growth enhancement
of mycobacteria by vitamin B3 (nicotinamide), nicotinic acid (a
tobaccoconstituent)anda&ßNAD[31].In1940thepossibilitythat
vitamin K enhanced the growth of MAP was considered [37]. (see
[38] for review). The identification of the necessary, and potent, iron
chelating mycobactins of M. phlei [39,40] (see [41] for review), left
unresolved a possible enhancing role of vitamin K on MAP growth
[37]. In this present study we observe no growth enhancement by
vitaminK1.Itisofin te re stho we ve r,th atvi ta mi nK 2(menaquinone),
which we did not evaluate, may inhibit mycobacterial growth [42].
We now conclude that vitamin K1 has no effect on the growth of
three mycobacterial species, including MAP.
This study does not address how vitamin concentrations that are
inhibitory in our culture system, relate to concentrations actually
found in multicellular organisms. For example our ‘‘normal’’
laboratory range in humans for circulating vitamin A is 0.3–
0.9 mg/ml, a level below those tested in our studies (1–64 mg/ml.)
Lipophylic antibiotics, such as azithromycin, may achieve tissue
levels 1,000 fold greater than circulating values [43]. Since
‘‘normal’’ laboratory concentrations are ‘‘circulating’’ plasma
levels, they may vastly underestimate concentrations that these
fat-soluble vitamins achieve in lipid rich regions, such as
prokaryotic and eukaryotic cell walls and other lipophylic regions
within cells.
Prevailing dogma considers that all of the anti-mycobacterial
activity of vitamins A & D is mediated, indirectly, via enhancement
of the immune system of the eukaryotic host. Our data are
compatible with an alternative hypothesis: In addition to their
eukaryotic activity, vitamins A & D may directly inhibit mycobac-
teria within the eukaryotic host. Similarly whether vitamins may act
as naturally occurring ‘‘antibiotics’’ and help prevent a host infected
by mycobacteria from progressing to active disease will require
extensive and complicated, IRB compliant, additional studies.
Nevertheless, it is of considerable interest that low exposure to
sunlight, which is associated with diminished vitamin D levels [44],
is associated with an increase inthe incidenceof Crohn disease[45],
which may be caused by MAP [46].
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Table 9. Retinoic Acid.
mg/ml MAP M. Avium M. tb. Complex
Human Isolate
Bovine
Isolate M. tb. BCG
UCF-4 Dominic 19698 303 25291 101 25177 19015
16 %24% 215% 2% 24% 0% 230% 11%
4 23% 222% 237% 2% 11% 7% 289% 15%
16 218% 233% 261% 214% 29% 236% 299% 0%
64 256% 248% 276% 221% 223% 254% 299% 1%
doi:10.1371/journal.pone.0029631.t009
Table 10. 13 Cis-Retinoic Acid.
mg/ml MAP M. Avium M. tb. Complex
Human Isolate
Bovine
Isolate M. tb. BCG
UCF-4 Dominic 19698 303 25291 101 25177 19015
10 %27% 218% 221% 12% 10% 216% 9%
4 223% 220% 234% 220% 25% 233% 242% 9%
16 218% 229% 258% 234% 227% 242% 291% 30%
32 235% 235% 268% 244% 234% 265% 297% 15%
doi:10.1371/journal.pone.0029631.t010
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